ERBB2 and breast carcinoma: Quite notably, the efficacy of combined therapies using lapatinib could be extended to other tissues colonized by metastatic breast cancer cells because dual HER2 blockade with trastuzumab and lapatinib inhibited tumor growth in patient-derived xenografts of HER2-amplified metastatic colorectal cancer [21].